Moclobemide
| Evidence Level: L2 | Predicted Indications: 2 |
Table of Contents
Moclobemide: From Anxiety Disorder to Agoraphobia
One-Sentence Summary
Moclobemide is a reversible inhibitor of monoamine oxidase A, originally used for anxiety disorder, neurotic disorder and dysthymic disorder. The TxGNN model predicts it may be effective for agoraphobia, with no registered clinical trials but 10 publications (2 randomised controlled trials among them) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder, neurotic disorder, dysthymic disorder |
| Predicted New Indication | Agoraphobia |
| TxGNN Prediction Score | 0.9943 |
| Evidence Level | L2 |
| India Market Status | Listed in a compiled Indian medicine price dataset (6 of 6) – CDSCO approval status is not included in this data |
| Number of Listed Products | 6 (valid: 6) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA). It raises synaptic serotonin, norepinephrine and dopamine. This is an inference from the drug class and not from the supplied record. The pharmacology data compiled for this report confirm that it targets MAO-A and MAO-B.
Agoraphobia usually occurs together with panic disorder, and it sits within the same family of anxiety disorders as moclobemide’s original indications. Panic disorder with agoraphobia responds to serotonergic and noradrenergic modulation, including SSRIs, tricyclic antidepressants and classical MAO inhibitors. This makes a benefit from moclobemide mechanistically plausible.
The published studies reinforce this. They include randomised trials in panic disorder with agoraphobia and open-label work in social phobia, a closely related condition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10448444 | 1999 | RCT | Br J Psychiatry | Placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia |
| 10361962 | 1999 | RCT | Eur Arch Psychiatry Clin Neurosci | Moclobemide (450 mg/day) vs clomipramine (150 mg/day) in panic disorder with and without agoraphobia; 135 patients, double-blind |
| 28867934 | 2017 | Review | Dialogues Clin Neurosci | Guideline-based treatment recommendations for anxiety disorders, including panic disorder/agoraphobia |
| 32002937 | 2020 | Review | Adv Exp Med Biol | Psychopharmacological treatment of anxiety disorders based on guidelines and meta-analyses |
| 7717094 | 1995 | Review | Acta Psychiatr Scand Suppl | Reversible MAO-A inhibitors (including moclobemide) in mental disorders; unequivocal antidepressant activity |
| 8313401 | 1993 | Review | Clin Neuropharmacol | Reversible MAO-A inhibitors in panic disorder; they need no dietary restrictions and are better tolerated |
| 12006898 | 2002 | Review / conceptual model | J Clin Psychopharmacol | Interactive model of therapeutic response in panic disorder, using moclobemide data |
| 7954487 | 1994 | Open-label pilot | Clin Neuropharmacol | 35 social phobia outpatients given 300–600 mg/day for 12 weeks; improvement in both fear and avoidance |
| 16850261 | 2006 | Comparative imaging study | Metab Brain Dis | Citalopram vs moclobemide effects on resting brain perfusion in social anxiety disorder |
| 7892341 | 1995 | Case report | Psychiatr Prax | Treatment-refractory panic disorder remitted with imipramine, moclobemide and behaviour therapy |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 189367 | Rimarex 150mg Capsule | Strip of 10 capsules | Not stated in the data |
| 191809 | Rimarex 300mg Capsule | Strip of 10 capsules | Not stated in the data |
| 138905 | Morex 150mg Tablet | Strip of 10 tablets | Not stated in the data |
| 143057 | Morex 300mg Tablet | Strip of 10 tablets | Not stated in the data |
| 221418 | Trima 150mg Tablet | Strip of 10 tablets | Not stated in the data |
Six valid single-ingredient registrations exist in total. The sixth is Trima 300mg Tablet (220789, Intas Pharmaceuticals).
Safety Considerations
- Drug Interactions: The pharmacology data show that moclobemide acts on monoamine oxidase A (MAOA) and monoamine oxidase B (MAOB). No specific interacting drugs or severity levels were identified. As with other MAO inhibitors, combinations with serotonergic or sympathomimetic agents need caution.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two randomised controlled trials in panic disorder with agoraphobia, plus several reviews, support efficacy, and the drug is already marketed in India. However, no clinical trial is registered for this indication, and the key safety and mechanism data are missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from the manufacturers (a blocking gap for safety screening)
- Detailed mechanism of action data
- Confirmation of the approved indication text for the Indian registrations
- Review of the two RCTs for agoraphobia-specific outcomes, since both enrolled panic disorder patients with or without agoraphobia
- A safety monitoring plan, with attention to interactions with serotonergic drugs
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.